Patents by Inventor Magnus Strandh
Magnus Strandh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10570192Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.Type: GrantFiled: September 28, 2017Date of Patent: February 25, 2020Assignee: Genentech, Inc.Inventors: Eric J. Brown, Martine Darwish, John Flygare, Wouter Hazenbos, Byoung Chul Lee, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
-
Publication number: 20180344846Abstract: The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.Type: ApplicationFiled: August 8, 2018Publication date: December 6, 2018Applicant: Symphogen A/SInventors: Johan Lantto, Kim Vilbour Andersen, Peter Sejer Andersen, Magnus Strandh, Klaus Koefoed, Lars Søgaard Nielsen, Mikkel Wandahl Pedersen, Helle Jacobsen, Michael Kragh, Ida Kjaer, Thomas Tuxen Poulsen
-
Patent number: 10058610Abstract: The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.Type: GrantFiled: November 14, 2016Date of Patent: August 28, 2018Assignee: Symphogen A/SInventors: Johan Lantto, Kim Vilbour Andersen, Peter Sejer Andersen, Magnus Strandh, Klaus Koefoed, Lars Søgaard Nielsen, Mikkel Wandahl Pedersen, Helle Jacobsen, Michael Kragh, Ida Kjaer, Thomas Tuxen Poulsen
-
Publication number: 20180085470Abstract: The invention provides anti-wall teichoic acid antibodies, antibiotic-linker intermediates, and antibody-antibiotic conjugate compound, and methods of making and using the same.Type: ApplicationFiled: December 7, 2017Publication date: March 29, 2018Applicant: Genentech, Inc.Inventors: Eric J. Brown, John Flygare, Wouter Hazenbos, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
-
Patent number: 9895450Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.Type: GrantFiled: November 19, 2015Date of Patent: February 20, 2018Assignee: Genentech, Inc.Inventors: Eric J. Brown, John Flygare, Wouter Hazenbos, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
-
Patent number: 9884126Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.Type: GrantFiled: May 22, 2014Date of Patent: February 6, 2018Assignee: Genentech, Inc.Inventors: Eric J. Brown, John Flygare, Wouter Hazenbos, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
-
Publication number: 20180016325Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.Type: ApplicationFiled: September 28, 2017Publication date: January 18, 2018Applicant: Genentech, Inc.Inventors: Eric J. Brown, Martine Darwish, John Flygare, Wouter Hazenbos, Byoung Chul Lee, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
-
Patent number: 9803002Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.Type: GrantFiled: May 30, 2014Date of Patent: October 31, 2017Assignee: Genentench, Inc.Inventors: Eric J. Brown, Martine Darwish, John Flygare, Wouter Hazenbos, Byoung Chul Lee, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
-
Publication number: 20170165365Abstract: The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.Type: ApplicationFiled: November 14, 2016Publication date: June 15, 2017Inventors: Johan Lantto, Kim Vilbour Andersen, Peter Sejer Andersen, Magnus Strandh, Klaus Koefoed, Lars Søgaard Nielsen, Mikkel Wandahl Pedersen, Helle Jacobsen, Michael Kragh, Ida Kjaer, Thomas Tuxen Poulsen
-
Patent number: 9527913Abstract: The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.Type: GrantFiled: May 2, 2013Date of Patent: December 27, 2016Assignee: SYMPHOGEN A/SInventors: Johan Lantto, Kim Vilbour Andersen, Peter Sejer Andersen, Magnus Strandh, Klaus Koefoed, Lars Søgaard Nielsen, Mikkel Wandahl Pedersen, Helle Jacobsen, Michael Kragh, Ida Kjær, Thomas Tuxen Poulsen
-
Publication number: 20160074529Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.Type: ApplicationFiled: November 19, 2015Publication date: March 17, 2016Applicant: GENENTECH, INC.Inventors: Eric J. Brown, John Flygare, Wouter Hazenbos, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
-
Publication number: 20150366985Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.Type: ApplicationFiled: May 22, 2014Publication date: December 24, 2015Applicant: GENENTECH, INC.Inventors: Eric J. Brown, John Flygare, Wouter Hazenbos, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
-
Publication number: 20150086478Abstract: The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.Type: ApplicationFiled: May 2, 2013Publication date: March 26, 2015Inventors: Johan Lantto, Kim Vilbour Andersen, Peter Sejr Andersen, Magnus Strandh, Klaus Koefoed, Lars Søgaard Nielsen, Mikkel Wandahl Pedersen, Helle Jacobsen, Michael Kragh, Ida Kjær, Thomas Tuxen Poulsen
-
Publication number: 20140356376Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.Type: ApplicationFiled: May 30, 2014Publication date: December 4, 2014Applicant: GENENTECH, INC.Inventors: Eric J. Brown, Martine Darwish, John Flygare, Wouter Hazenbos, Byoung Chul Lee, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
-
Publication number: 20140356375Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.Type: ApplicationFiled: May 22, 2014Publication date: December 4, 2014Applicant: GENENTECH, INC.Inventors: Eric J. Brown, Martine Darwish, John Flygare, Wouter Hazenbos, Byoung Chul Lee, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
-
Publication number: 20040185467Abstract: Improved methods using microscope based detection for identifying nucleic acid polymorphisms rely on localizing the region to be tested using particulate labels. The length of a segment containing tandem repeats can be determined by the intensity of signal emitted by a fluorophore associated with the repeat and bracketed by the labels; the presence of an allele containing a restriction site can be identified by viewing the association or dissociation of particulate labels. Single nucleotide polymorphisms characterized by the presence or absence of a referent base can be detected with a large differential in binding energy using short probes, by virtue of localizing the base to be interrogated with flanking particulate labels. The methods may be performed on a multiplicity of test nucleic acids simultaneously by employing a multiplicity of particulate labels with differing hues.Type: ApplicationFiled: November 13, 2003Publication date: September 23, 2004Inventors: Lawrence M. Kauvar, Magnus Strandh, Remy Cromer